A novel method for boronating antibodies without loss of immunoreactivity, for use in neutron capture therapy.
The search for suitable boron containing compounds for 10B neutron capture therapy (BNCT) is based on the principle that boron atoms must be delivered specifically to tumour cells at a concentration high enough to be effective without being toxic to normal cells. Specificity may be achieved through monoclonal antibodies. However, it has been difficult to conjugate large numbers of boron atoms to the antibody molecules without inactivating them. We have devised a strategy to do this indirectly through the use of a boronated glutamate-lysine polymer in conjunction with biotin and streptavidin.
Ferro
V A
VA
Department of Immunology, University of Strathclyde, Todd Centre, Glasgow, UK.
Morris
J H
JH
Stimson
W H
WH
D000906:Antibodies / Q000737:chemistry* / Q000276:immunology; D000918:Antibody Specificity; D001426:Bacterial Proteins / Q000737:chemistry; D001896:Boron Compounds / Q000737:chemistry* / Q000276:immunology; D016754:Boron Neutron Capture Therapy / Q000379:methods*; D018288:Carcinoma, Small Cell / Q000532:radiotherapy; D016923:Cell Death; D006801:Humans; D008175:Lung Neoplasms / Q000532:radiotherapy; D011099:Polyglutamic Acid / Q000031:analogs & derivatives / Q000737:chemistry; D011107:Polylysine / Q000031:analogs & derivatives / Q000737:chemistry; D019809:Streptavidin; D014407:Tumor Cells, Cultured
D000906:Antibodies; D001426:Bacterial Proteins; D001896:Boron Compounds; D011107:Polylysine; D011099:Polyglutamic Acid; C030391:poly(glutamic acid-lysine); D019809:Streptavidin